A two-part, phase I study of single and repeat doses of dipraglurant (ADX 48621) in healthy volunteers.

Trial Profile

A two-part, phase I study of single and repeat doses of dipraglurant (ADX 48621) in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2009

At a glance

  • Drugs Dipraglurant (Primary)
  • Indications Anxiety disorders; Depressive disorders; Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Addex Therapeutics
  • Most Recent Events

    • 28 Jan 2009 Status changed from recruiting to completed, as reported in Addex Pharmaceuticals media release.
    • 28 Oct 2008 Addex Pharmaceuticals has announced that the first part of this study has been completed.
    • 28 Oct 2008 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top